Literature DB >> 23708064

Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma?

George Philips1, Michael B Atkins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708064     DOI: 10.1097/PPO.0b013e318292e6a2

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  1 in total

1.  A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2).

Authors:  Xiaofang Hu; Yan Cao; Yiming Meng; Mingxiao Hou
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.